Chemical Biology Program
The Minkui Luo Lab
The projects of this laboratory aim to leverage cutting-edge approaches in combination of chemistry and biology to annotate, perturb and manipulate essential functions of protein methyltransferases implicated in epigenetic biology and cancer. The Luo laboratory is also interested in designing and synthesizing inhibitors as potential anti-cancer drugs with the emphasis of their distinct modes of action and wise uses in relevant disease contexts. Researchers in the field of chemistry, biochemistry and biology work in a highly collaborative manner to synthesize novel chemical reagents, elucidate disease-causing mechanisms at molecular levels, and develop potential treatments for human diseases.
Joshua A. Linscott, Kanishk Kapilashrami, Zhen Wang, Chamara Senevirathne, Ian R. Bothwell, Gil Blum, Minkui Luo, “Kinetic Isotope Effects Reveal Early SN2 Transition State of SET8-catalyzed Protein Lysine Methylation”, Proc. Natl. Acad. Sci. U.S.A. 2016, 113, E8369.
Zhang L, Tran NT, Su H, Wang R, Lu Y, Tang H, Aoyagi S, Guo A, Khodadadi-Jamayran A, Zhou D, Qian K, Hricik T, Côté J, Han X, Zhou W, Laha S, Abdel-Wahab O, Levine RL, Raffel G, Liu Y, Chen D, Li H, Townes T, Wang H, Deng H, Zheng YG, Leslie C, Luo M, Zhao X. “Cross-talk between PRMT1-mediated methylation and ubiquitylation on RBM15 controls RNA splicing”, Elife, 2015, e07938
Minkui Luo, PhD
- Chemical Biologist Minkui Luo develops cutting-edge tools, technologies and concepts to annotate functions of protein-posttranslational modifications and designs inhibitors for cancer therapies.
- BS, Fudan University
- PhD, Princeton University
- Eli Lilly Award in Biological Chemistry, American Chemical Society (2015)
- Clinical & Translational Science Center Novel Award, Weill Cornell Medical College (2014)
- Basil O'Connor Starter Scholar, March of Dimes Birth Defects Foundation (2011)
- Director’s New Innovator Award, National Institutes of Health (2010)
- Alfred W. Bressler Scholar, Alfred W. Bressler Scholars Endowment Fund (2010)
- V Scholar Award, V Foundation for Cancer Research (2009)
- Outstanding Postdoctoral Research Prize, Albert Einstein College of Medicine (2007)
Get in Touch
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Minkui Luo discloses the following relationships and financial interests:
Provision of Services
Provision of Services
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2019 through disclosure submission in spring 2020). This data reflects interests that may or may not still exist. This data is updated annually.